StockNews.AI
INO
StockNews.AI
15 days

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

1. INO will release Q2 2025 financial results on August 12. 2. Live conference call to follow results announcement. 3. INO focuses on DNA medicines for HPV-related diseases. 4. Webcast will feature analyst Q&A and be archived for 90 days.

4m saved
Insight
Article

FAQ

Why Neutral?

The announcement of financial results holds neutral sentiment as it is routine. Historical data shows similar events do not typically drive significant market moves unless results are unexpected.

How important is it?

While earnings reports can affect stock prices, expectations are likely already priced in.

Why Short Term?

Immediate interest due to upcoming earnings report; however, lasting impact depends on results.

Related Companies

NVAXMRNABNTX
, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event. About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com. ContactsMedia: Jennie Willson, (267) 429-8567, [email protected]Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, [email protected]  SOURCE INOVIO Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News